[Experience in the clinical use of etmozin in different cardiac rhythm disturbances].
The results of treating 95 patients suffering from various disorders of cardiac rhythm with ethmosin are discussed. Sixty-eight patients received oral ethmosin in a daily dose of 600 mg, 12 of them were treated for a long time (85 +/- 39 days on the average), the others for no more than 3--7 days. Fifty patients received a daily dose of 150 mg ethmosin in a single intravenous injection. The therapeutic effect was considered positive if the number of extrasystoles reduced by no less than 50% with complete removal of group extrasystoles and paroxysms of tachycardia according to the data of daily monitoring observation of the ECG and bicycle ergometry. In medication with oral ethmosin a positive effect was achieved in 34 of 55 patients with ventricular extrasystole, in 1 of 5 with atrial extrasystole, in 2 of 5 with paroxysmal tachycardia in the presence of the Wolff--Parkinson--White syndrome, and in 1 patient with paroxysmal atrial tachycardia. In intravenous ethmosin administration ventricular extrasystole was corrected in 12 of 15 patients, atrial in 3 of 6, ventricular tachycardia in 4 of 7, paroxysmal tachycardia with the Wolff--Parkinson--White syndrome in 4 of 5, atrial fibrillation in 1 of 9, atrial tachycardia in 1 of 6; no effect was produced in either of 2 patients with atrial flutter. Oral ethmosin did not produce any side-effects.
D000293:Adolescent; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D016293:Moricizine; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use; D010640:Phenothiazines / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D009025:Morpholines; D010640:Phenothiazines; D016293:Moricizine
Opyt klinicheskogo primeneniia étmozina pri razlichnykh narusheniiakh ritma serdtsa.